%	O
%	O
TITLE	O

Relationship	O
between	O
p16	O
expression	O
and	O
prognosis	O
in	O
different	O
anatomic	O
subsites	O
of	O
OSCC	O
.	O

%	O
%	O
ABSTRACT	O

p16	O
has	O
often	O
been	O
found	O
to	O
be	O
overexpressed	O
in	O
patients	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
,	O
but	O
its	O
prognostic	O
value	O
between	O
anatomic	O
subsites	O
is	O
still	O
unclear	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
diagnostic	O
and	O
prognostic	O
values	O
of	O
p16	O
in	O
OSCC	O
originating	O
from	O
tongue	O
,	O
gingiva	O
or	O
buccal	O
mucosa	O
.	O
A	O
total	O
of	O
147	O
OSCC	O
patients	O
with	O
tumors	O
arising	O
from	O
the	O
tongue	O
,	O
gingiva	O
or	O
buccal	O
mucosa	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

p16	O
expression	O
was	O
detected	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
,	O
and	O
the	O
presence	O
of	O
HPV16	O
was	O
determined	O
by	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
in	O
p16	B-Study_Cohort
positive	I-Study_Cohort
patients	I-Study_Cohort
.	O

The	O
correlation	O
of	O
p16	O
expression	O
with	O
the	O
clinical	O
parameters	O
was	O
evaluated	O
.	O
Only	O
one	O
p16	O
positive	O
patient	O
with	O
a	O
cut	O
off	O
value	O
of	O
25	O
%	O
and	O
75	O
%	O
was	O
HPV16	O
positive	O
.	O

Although	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
recurrence	O
free	O
survival	O
(	O
RFS	O
)	O
and	O
metastasis	O
free	O
survival	O
(	O
MFS	O
)	O
had	O
no	O
significant	O
differences	O
between	O
the	O
p16	O
positive	O
and	O
negative	O
patients	O
,	O
p16	O
negative	O
patients	O
(	O
cut	O
off	O
value	O
25	O
%	O
)	O
had	O
more	O
RFS	O
in	O
the	O
buccal	O
mucosa	O
cancer	O
(	O
p=	O
0	O
.	O
03	O
)	O
than	O
the	O
p16	O
-	O
positive	O
patients	O
.	O
The	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV16	O
in	O
Chinese	B-Study_Location
OSCC	O
patients	O
was	O
low	O
.	O

p16	O
overexpression	O
decoupled	O
from	O
HPV	O
infection	O
was	O
not	O
a	O
prognostic	O
marker	O
for	O
OSCC	O
patients	O
except	O
for	O
patients	O
with	O
the	O
buccal	O
mucosa	O
cancer	O
.	O

%	O
%	O
MATERIAL	O
AND	O
METHODS	O

Study	O
population	O
and	O
design	O

Samples	B-HPV_Sample_Type
and	O
the	O
follow	O
-	O
up	O
data	O
of	O
147	O
eligible	O

tained	O
from	O
the	O
head	O
and	O
neck	O
tumor	O
bio	O
-	O
bank	O
of	O
Nanjing	O
Stomatological	O
Hospital	O
,	O
Medical	O
school	O
of	O
Nanjing	O
University	O
.	O

All	O
the	O
enrolled	O
patients	O
under	O
-	O
went	O
surgeries	O
in	O
the	O
department	O
of	O
Oral	O
and	O
Max	O
-	O
illofacial	O
Surgery	O
,	O
Nanjing	O
Stomatological	O
hospital	O
be	O
-	O
tween	O
February	B-Study_Time
1	I-Study_Time
,	I-Study_Time
2013	I-Study_Time
and	I-Study_Time
November	I-Study_Time
13	I-Study_Time
,	I-Study_Time
2014	I-Study_Time
.	I-Study_Time

Specifically	O
,	O
the	O
OSCC	O
primary	O
tumors	O
were	O
removed	O
with	O
adequate	O
surgical	O
margins	O
,	O
which	O
were	O
sent	O
for	O
histopathology	O
analysis	O
.	O

If	O
margins	O
were	O
not	O
deemed	O
to	O
be	O
tumor	O
free	O
,	O
further	O
resection	O
was	O
performed	O
.	O

A	O
total	O
of	O
136	O
/	O
147	O
(	O
92	O
.	O
5	O
%	O
)	O
of	O
patients	O
received	O
follow	O
-	O
up	O
examinations	O
every	O
two	O
months	O
after	O
surgery	O
un	O
-	O
til	O
death	O
.	O

Follow	O
-	O
up	O
visits	O
continued	O
until	O
February	O
9	O
,	O
2018	O
,	O
and	O
only	O
7	O
.	O
5	O
%	O
(	O
11	O
/	O
147	O
)	O
of	O
patients	O
did	O
not	O
at	O
-	O
tend	O
the	O
follow	O
-	O
up	O
appointment	O
because	O
of	O
an	O
incorrect	O
phone	O
number	O
or	O
address	O
.	O

This	O
study	O
was	O
conducted	O
according	O
to	O
the	O
ethical	O
principles	O
of	O
the	O
Helsinki	O
Declaration	O
and	O
approved	O
by	O
Nanjing	O
Stomatological	O
Hospital	O
ethics	O
committee	O
(	O
date	O
of	O
approval	O
,	O
26th	O
February	O
2018	O
;	O
approval	O
num	O
-	O
ber	O
2018NL	O
-	O
022	O
(	O
KS	O
)	O
)	O
.	O

p16	B-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique

Paraffin	O
sections	O
(	O
4	O
-	O
µm	O
thick	O
)	O
of	O
tumor	O
tissues	B-HPV_Sample_Type
were	O
deparaffinized	O
and	O
treated	O
with	O
10	O
mM	O
citrate	O
buffer	O
at	O
92◦C	O
for	O
30	O
minutes	O
for	O
antigen	O
retrieval	O
.	O

After	O
block	O
-	O
ing	O
in	O
10	O
%	O
bovine	O
serum	O
albumin	O
,	O
the	O
slides	O
were	O
im	O
-	O
munostained	O
for	O
a	O
mouse	O
monoclonal	O
anti	O
-	O
p16	O
(	O
MTM	O
Laboratories	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

p16	O
expression	O
was	O
rated	O
by	O
two	O
pathologists	O
without	O
patient	O
details	O
according	O
to	O
the	O
fraction	O
of	O
positive	O
cells	O
:	O
negative	O

staining	O
=	O
0	O
,	O
1–5	O
%	O
=	O
1	O
,	O
6–25	O
%	O
=	O
2	O
,	O
26–75	O
%	O
=	O
3	O
,	O
>	O

75	O
%	O
=	O
4	O
.	O

DNA	O
extraction	O
from	O
FFPE	O
tissues	O

Samples	B-HPV_Sample_Type
that	O
met	O
the	O
criteria	O
for	O
inclusion	O
were	O
then	O
re	O
-	O
cut	O
into	O
10	O
-	O
µm	O
thickness	O
and	O
mounted	O
on	O
adher	O
-	O
ent	O
slides	O
.	O

After	O
scraping	O
the	O
tumor	O
and	O
adjacent	O
non	O
-	O
tumor	O
cells	O
onto	O
the	O
slides	O
,	O
DNA	O
was	O
obtained	O
by	O
using	O
the	O
QIAamp	O
DNA	O
FFPE	O
Tissue	O
kit	O
(	O
Qiagen	O
Inc	O
.	O
,	O
Va	O
-	O
lencia	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturers’	O
direction	O
.	O

Then	O
,	O
DNA	O
concentration	O
and	O
quality	O
were	O
assessed	O
by	O
Nanodrop	O
.	O

Real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique

All	B-HPV_Lab_Technique
samples	I-HPV_Lab_Technique
were	I-HPV_Lab_Technique
run	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
triplicate	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
a	I-HPV_Lab_Technique
10	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
µL	I-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique
mix	I-HPV_Lab_Technique
containing	I-HPV_Lab_Technique
25	I-HPV_Lab_Technique
to	I-HPV_Lab_Technique
50	I-HPV_Lab_Technique
ng	I-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
5	I-HPV_Lab_Technique
µL	I-HPV_Lab_Technique
PowerUpTM	I-HPV_Lab_Technique

histopathologically	O
confirmed	O
OSCC	O
patients	O
were	O
ob	O
-	O

SYBRQ	O

Green	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
,	O
Life	O

Table	O
1	O

Sequence	O
of	O
HPV16	O
E6	O
/	O
E7	O
and	O
β	O
-	O
globin	O
primers	O
used	O
for	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique

Name	O
Sequence	O

HPV16	O
E6	O
-	O
F	O
GTCATATACCTCACGTCGCAG	O
HPV16	O
E6	O
-	O
R	O
AGCGACCCAGAAAGTTACCAC	O
HPV16	O
E7	O
-	O
F	O
AGTGTGACTCTACGCTTCGG	O
HPV16	O
E7	O
-	O
R	O
CTGCAGGATCAGCCATGGTA	O
β	O
-	O
globin	O
-	O
F	O
CAACTTCATCCACGTTCACC	O

β	O
-	O
globin	O
-	O
R	O
GAAGAGCCAAGGACAGGTAC	O

Table	O
2	O

Baseline	O
characteristics	O
of	O
OSCC	O
patients	O
(	O
n	O
=	O
147	O
)	O
Characteristics	O
No	O
(	O
%	O
)	O

Age	O
at	O
diagnosis	O
,	O
median	O
(	O
range	O
)	O
62	O
(	O
28–85	O
)	O

Gender	O

Male	O
79	O
(	O
53	O
.	O
74	O
%	O
)	O

Female	O
68	O
(	O
46	O
.	O
26	O
%	O
)	O

Smoking	O
status	O
at	O
diagnosis	O

P	O

Tumor	O
classification	O

T1	O
45	O
(	O
30	O
.	O
61	O
%	O
)	O

T2	O
81	O
(	O
55	O
.	O
1	O
%	O
)	O

T3	O
9	O
(	O
6	O
.	O
12	O
%	O
)	O

T4	O
12	O
(	O
8	O
.	O
16	O
%	O
)	O

Nodal	O
classification	O

Poor	O
differentiation	O
107	O
(	O
72	O
.	O
79	O
%	O
)	O

Moderate	O
to	O
well	O
differentiation	O
40	O
(	O
27	O
.	O
21	O
%	O
)	O

p16	O
status	O

<	O
25	O
%	O
126	O
(	O
85	O
.	O
71	O
%	O
)	O

>	O
25	O
%	O
21	O
(	O
14	O
.	O
29	O
%	O
)	O

<	O
75	O
%	O
140	O
(	O
95	O
.	O
24	O
%	O
)	O

>	O
75	O
%	O
7	O
(	O
4	O
.	O
76	O
%	O
)	O

Technologies	O
,	O
Austin	O
,	O
TX	O
,	O
USA	B-Study_Location
)	O
and	O
0	O
.	O
2	O
µM	O
of	O
each	O
primer	O
.	O

The	O
samples	B-HPV_Sample_Type
were	O
classified	O
as	O
HPV	O
positive	O
if	O
two	O
or	O
three	O
wells	O
of	O
the	O
triplicate	O
showed	O
an	O
am	O
-	O
plifying	O
curve	O
and	O
only	O
one	O
peak	O
in	O
the	O
melt	O
curve	O
.	O

CaSki	O
,	O
an	O
HPV	O
-	O
containing	O
cell	O
line	O
,	O
was	O
used	O
as	O
the	O
positive	O
control	O
and	O
Fadu	O
,	O
an	O
HPV	O
negative	O
cell	O
line	O
,	O
was	O
used	O
as	O
the	O
negative	O
control	O
.	O

In	O
order	O
to	O
exclude	O
environmental	O
contamination	O
,	O
a	O
negative	O
control	O
with	O
-	O
out	O
DNA	O
templates	O
was	O
also	O
evaluated	O
.	O

A	O
standard	O
curve	O
of	O
HPV16	O
E6	O
/	O
E7	O
and	O
E7	O
was	O
developed	O
using	O
a	O
5	O
-	O
fold	O
diluted	O
DNA	O
extracted	O
from	O
the	O
Caski	O
cell	O
line	O
.	O

All	O
primers	O
are	O
shown	O
in	O
Table	O
.	O

Statistical	O
analysis	O

Correlation	O
of	O
p16	O
expression	O
to	O
the	O
clinical	O
param	O
-	O
eters	O
was	O
evaluated	O
with	O
the	O
chi	O
-	O
square	O
test	O
.	O

OS	O
was	O
defined	O
as	O
the	O
time	O
from	O
the	O
date	O
of	O
surgery	O
to	O
the	O
date	O
of	O
death	O
or	O
the	O
date	O
of	O
censorship	O
.	O

RFS	O
was	O
defined	O
as	O
the	O
time	O
of	O
surgery	O
to	O
the	O
date	O
of	O
recurrence	O
and	O
re	O
-	O
lapse	O
or	O
the	O
date	O
of	O
censorship	O
.	O

MFS	O
was	O
defined	O
as	O
the	O
time	O
of	O
surgery	O
to	O
the	O
date	O
of	O
metastasis	O
or	O
the	O
date	O
of	O
censorship	O
.	O

The	O
OS	O
,	O
RFS	O
and	O
MFS	O
were	O
estimated	O
with	O
Kaplan	O
-	O
Meier	O
methods	O
for	O
all	O
patients	O
and	O
sub	O
-	O
populations	O
with	O
different	O
anatomic	O
subsites	O
.	O

Log	O
rank	O
tests	O
were	O
performed	O
to	O
test	O
the	O
differences	O
in	O
survival	O
between	O
p16	O
-	O
positive	O
and	O
p16	O
-	O
negative	O
patients	O
with	O
25	O
%	O
and	O
75	O
%	O
cut	O
off	O
values	O
,	O
which	O
were	O
previously	O
used	O
to	O
determine	O
p16	O
positivity	O
.	O

Univariate	O
and	O
multi	O
-	O
variate	O
analyses	O
of	O
all	O
patients	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
were	O
performed	O
using	O
the	O
follow	O
-	O
ing	O
variables	O
:	O
age	O
,	O
primary	O
tumor	O
location	O
,	O
TNM	O
,	O
dif	O
-	O
ferentiation	O
,	O
metastasis	O
,	O
recurrence	O
and	O
p16	O
positivity	O
.	O

In	O
all	O
statistical	O
tests	O
,	O
a	O
p	O
value	O
of	O
0	O
.	O
05	O
or	O
below	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O

